Neuroendocrine Carcinoma
📧 Sign up to get email alerts when something new happens for Neuroendocrine Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity [Phase 2]
A Phase 2 clinical trial update exploring belinostat pharmacokinetics and toxicity guided by UGT1A1 genotype in neuroendocrine tumors.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma [Phase 2]
A Phase II clinical trial of SHR-A1904 as monotherapy for second-line or later treatment of advanced neuroendocrine carcinoma, with status l…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors [Phase 1]
First-in-human Phase 1 trial update of the antibody-drug conjugate ADCT-701 in patients with neuroendocrine tumors, neuroendocrine carcinoma…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is enrolling to evaluate LBL-024 with etoposide and platinum in patients with advanced neuroendocrine carcinoma.
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: DLL3-Targeted PET/CT in Neuroendocrine Carcinoma [NA]
A DLL3-targeted PET/CT imaging trial for DLL3-expressing neuroendocrine tumors is currently recruiting at The First Affiliated Hospital of X…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Study of Oral MRT-2359 in Selected Cancer Patients [Phase 1, Phase 2]
Ongoing Phase 1/Phase 2 trial evaluating MRT-2359 in multiple cancer indications; trial is active but not recruiting.
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating MK-6070 (HPN328-4001), a DLL3-targeted therapy, in advanced cancers expressing DLL3, including small c…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC [Phase 1]
A Phase I study to evaluate the safety, tolerability, and pharmacokinetics of HLX3901 in patients with advanced small cell lung cancer or ne…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors [Phase 1]
Phase 1 clinical trial update on the investigational agent BL-M14D1 for locally advanced or metastatic small cell lung cancer and a range of…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: FTT PET/CT in Pancreatic Neuroendocrine Tumors [Phase 1]
A Phase 1 clinical trial evaluating FTT PET/CT imaging in pancreatic neuroendocrine tumors is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer [Phase 1, Phase 2]
IDEAYA Biosciences is conducting a Phase 1/2 trial of IDE849 in DLL3-expressing tumors, including small cell lung cancer and neuroendocrine …
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors [Phase 2]
Status update on a Phase 2 trial of nivolumab plus ipilimumab for advanced rare genitourinary tumors; the study is currently active but not …
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma [Phase 1, Phase 2]
An ongoing Phase 1/2 clinical trial of ZG006 for Small cell lung cancer and neuroendocrine carcinoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma [Phase 1, Phase 2]
This clinical trial update reports that ZG005 and ZG006 are being studied in Phase 1/Phase 2 trials for small cell lung cancer and neuroendo…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors [Phase 2]
CVM-1118 is being studied in a Phase 2 trial for advanced neuroendocrine tumors. The study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Neuroendocrine Tumors - Patient Reported Outcomes
Clinical trial update on patient-reported outcomes for neuroendocrine tumors in the NCT05064150 study sponsored by the University of Iowa; t…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer [Phase 2]
Phase 2 clinical trial update evaluating nivolumab plus temozolomide in patients with recurrent or refractory small-cell lung cancer or adva…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) [Phase 1]
Phase 1 clinical trial evaluating the combination of SVV-001 with nivolumab and ipilimumab in patients with poorly differentiated neuroendoc…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) [Phase 2]
Phase 2 clinical trial update assessing tarlatamab (AMG 757) in metastatic/locally advanced small-cell lung cancer and other poorly differen…
-
CLINICAL_TRIALS research · 2025-11-13Clinical Trial Update: RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
RegisterNET is a registry for neuroendocrine tumors in the USA and worldwide. It is currently enrolling by invitation.
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary [Phase 2]
A Phase 2 clinical trial evaluating chemotherapy for metastatic, poorly differentiated Grade 3 neuroendocrine carcinoma of gastroenteropancr…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
This Clinical Trial Update discusses patient journeys and treatment outcomes for neuroendocrine carcinomas in Latin America; the trial NCT07…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) [Phase 1, Phase 2]
Phase 1/2 SKYBRIDGE study evaluating Peluntamig (PT217) in DLL3-expressing neuroendocrine carcinomas; currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors [Phase 1, Phase 2]
An ongoing Phase 1/2 study investigates systemic VSV-IFNβ-NIS in combination with checkpoint inhibitors for select solid tumors. The trial i…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas [Phase 1]
Phase 1 clinical trial update for NP-101 (TQ Formula) in combination with nivolumab and ipilimumab for advanced or metastatic extra-pulmonar…